3rd Antigen-Specific Immune Tolerance Drug Development Summit

3rd Antigen-Specific Immune Tolerance Drug Development Summit is organized by Hanson Wade and will be held from Feb 25 - 27, 2020 at The Colonnade Hotel, Boston, Massachusetts, United States of America.

Description:
The meeting will bring together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen-specific immunotherapies, ASIT 2020 is the only antigen-specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.

Join the 3rd Antigen-Specific Immune Tolerance Summit to:
• Hear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk, Pfizer, Merck, Eli Lilly, ITN & FDA
• Explore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction
• Engage with and immerse yourself within a learning journey across three conference days, tackling all elements of drug development from discovery to clinical development
• Gain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials
• Employ novel therapeutics in combination with antigen-specific immunotherapies and drive the progression of drug development towards the clinic
• Take advantage of intimate networking opportunities with key opinion leaders from large pharma, biotech and academia through discursive and engaging platforms that spark conversation and debate

WorkShop Day:
Workshop A: Optimizing Novel Target Discovery
Tuesday February 25: 9:00am-12:00pm

Workshop B: Tolerance Induction in Antigen-Specific Immunotherapies: Applications to Transplantation
Tuesday February 25: 1:00pm-4:00pm

Time: 9:00 am - 6:00 pm

Additional details will be posted as soon as information is available.